The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Capital Medical University

Status: Completed

Conditions: Mycoplasma Pneumonia

Treatments: Drug: Cephalosporins and azithromycin; Drug: Moxifloxacin

Study type: Interventional

Funder types: Other

Identifiers

NCT01259141

MP201011

Details and patient eligibility

About

Mycoplasma pneumoniae, an important pathogen of community acquired pneumonia,are becoming more and more resistant to macrolide. The study aim is to optimize anti-infection therapy.

Full description

Mycoplasma pneumoniae was one of important atypical pathogens of community acquired pneumonia. As lack of cell wall, β-lactam medicines were invalid, however, macrolides, tetracyclines and quinolones were effective. But from 2001, many countries reported macrolide- resistant Mycoplasma pneumoniae. Typically, erythromycin was first-line antibiotic medicine. With the resistance increasing, Mycoplasm pneumonia treatment will become more and more difficult. Thus, optimization of Mycoplasm pneumonia antibiotic therapy is very important.

Enrollment: 208 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Confirmed community acquired pneumonia
2. 60ys≥age≥18 ys
3. Respiratory symptom (cough accompanied by little or no sputum)
4. New infiltration showed by chest radiology(x-ray or CT)
5. Lung signs was not obvious
6. White blood cell<10,000/mm3
7. Without underlying diseases or mild

Exclusion criteria

1. Age<18ys or >60ys
2. Pregnancy or breast-feeding
3. Over one week after the onset of symptoms
4. HIV infection
5. Recent 90-day hospitalized history(length of stay greater than 2 days)
6. Live in nursing homes or rehabilitation hospitals
7. Taken macrolides or quinolones medicines before enrollment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

208 participants in 2 patient groups

Moxifloxacin

Experimental group

Treatment:

Drug: Moxifloxacin

Cephalosporins and azithromycin

Experimental group

Treatment:

Drug: Cephalosporins and azithromycin